摘要
Hepatocellular carcinoma(HCC)ranks the fourth cause of cancer-related death worldwide[1].More than 50%newly diagnosed HCC patients are in China,while 70%of them are at advanced stage when they are diagnosed[2].These patients have lost the opportunity of radical surgery and can only receive palliative care.Currently,the modality for these advanced stage HCC patients mainly include:targeted therapy,interventional therapy,chemotherapy,radiotherapy,and immunotherapy.
基金
supported by grants from National Natural Science Foundation of China(81502509 and 81872508)
